Osteoprotegerin in Bone Metastases: Mathematical Solution to the Puzzle

PLoS Computational Biology

Volumn 8, Issue 10, 2012, Pages

  Ryser, Marc D ^a,b   Qu, Yiding ^a   Komarova, Svetlana V ^a  

^a MCGILL UNIVERSITY   (Canada)

^b DUKE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE; CANCER CELLS; CELLS; DISEASES; NONLINEAR EQUATIONS; PARTIAL DIFFERENTIAL EQUATIONS; PATHOLOGY; UROLOGY;

BONE METASTASIS; CANCER CELLS; CANCER METASTASIS; CYTOKINES; MATHEMATICAL SOLUTIONS; METASTATIC TUMORS; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPROTEGERIN; PROSTATE CANCERS;

TUMORS;

EID: 84868131986     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1002703     Document Type: Article

References (58)

1. Mundy G, (2002) Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593.
2. Coleman R, Rubens R, (1987) The clinical course of bone metastases from breast cancer. Brit J Cancer 55: 61.
3. Kearns A, Khosla S, Kostenuik P, (2008) Receptor activator of nuclear factor κB ligand and osteo-protegerin regulation of bone remodeling in health and disease. Endocr Rev 29: 155-192.
4. Parfitt A, (1994) Osteonal and hemi-osteonal remodeling: The spatial and temporal framework for signal traffic in adult human bone. J Cell Biochem 55: 273-286.
5. Henriksen K, Neutzsky-Wulff A, Bonewald L, Karsdal M, (2009) Local communication on and within bone controls bone remodeling. Bone 44: 1026-1033.
6. Ryser M, Nigam N, Komarova S, (2009) Mathematical modeling of spatio-temporal dynamics of a single bone multicellular unit. J Bone Miner Res 24: 860-870.
7. Boyde A, Maconnachie E, Reid S, Delling G, Mundy G, (1986) Scanning electron microscopy in bone pathology: review of methods, potential and applications. Scan Elecron Microsc (Pt 4) pp. 1537-1554.
8. Morony S, Capparelli C, Sarosi I, Lacey D, Dunstan C, et al. (2001) Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis. Cancer Res 61: 4432-4436.
9. Corey E, Brown L, Kiefer J, Quinn J, Pitts T, et al. (2005) Osteoprotegerin in prostate cancer bone metastasis. Cancer Res 65: 1710.
10. Brown J, Vessella R, Kostenuik P, Dunstan C, Lange P, et al. (2001) Serum osteoprotegerin levels are increased in patients with advanced prostate cancer. Clin Cancer Res 7: 2977-2983.
11. Chen G, Sircar K, Aprikian A, Potti A, Goltzman D, et al. (2006) Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation. Cancer 107: 289-298.
12. Fisher J, Thomas-Mudge R, Elliott J, Hards D, Sims N, et al. (2006) Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res 66: 3620-3628.
13. Chamoux E, Houde N, L'Eriger K, Roux S, (2008) Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J Cell Physiol 216: 536-542.
14. Zauli G, Rimondi E, Stea S, Baruffaldi F, Stebel M, et al. (2008) TRAIL inhibits osteoclastic differentiation by counteracting RANKL-dependent p27Kip1 accumulation in pre-osteoclast precursors. J Cell Physiol 214: 117-125.
15. Zauli G, Rimondi E, Secchiero P, (2008) Soluble TRAIL does not impair the anti-osteoclastic activity of osteoprotegerin. J Cell Mol Med 12: 1063-1065.
16. Jones H, Nakashima T, Sanchez O, Kozieradzki I, Komarova S, et al. (2006) Regulation of cancer cell migration and bone metastasis by RANKL. Nature 440: 692-696.
17. Ryser M, Komarova S, Nigam N, (2010) The Cellular Dynamics of Bone Remodeling: A Mathe-matical Model. SIAM J Appl Math 70: 1899-1921.
18. Keller E, Brown J, (2004) Prostate cancer bone metastases promote both osteolytic and osteoblastic activity. J Cell Biochem 91: 718-729.
19. Lee W, Marshall J, Sissons H, (1965) Calcium accretion and bone formation in dogs: an experi-mental comparison between the results of ca45 kinetic analysis and tetracycline labelling. J Bone Joint Surg Br 47: 157.
20. Shapiro C, Manola J, Leboff M, (2001) Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol 19: 3306.
21. Wei J, Gross M, Jaffe C, Gravlin K, Lahaie M, et al. (1999) Androgen deprivation therapy for prostate cancer results in significant loss of bone density. Urology 54: 607-611.
22. Manabe N, Kawaguchi H, Chikuda H, Miyaura C, Inada M, et al. (2001) Connection between B lymphocyte and osteoclast differentiation pathways. J Immunol 167: 2625-2631.
23. Lacey D, Timms E, Tan H, Kelley M, Dunstan C, et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176.
24. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, et al. (1998) Osteoclast Differentiation Factor is a Ligand for Osteoprotegerin/Osteoclastogenesis-Inhibitory Factor and is Identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 95: 3597-3602.
25. Zhao S, Kato Y, Zhang Y, Harris S, Ahuja S, et al. (2002) MLO-Y4 Osteocyte-Like Cells Support Osteoclast Formation and Activation. J Bone Miner Res 17: 2068-2079.
26. Mosheimer B, Kaneider N, Feistritzer C, Sturn D, Wiedermann C, (2004) Expression and function of RANK in human monocyte chemotaxis. Arthritis Rheum 50: 2309-2316.
27. Henriksen K, Karsdal M, Delaissé J, Engsig M, (2003) RANKL and vascular endothelial growth factor (VEGF) induce osteoclast chemotaxis through an ERK1/2-dependent mechanism. J Biol Chem 278: 48745.
28. Jones D, Kong Y, Penninger J, (2002) Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis 61: ii32-ii39.
29. Alarcon T, Byrne H, Maini P, (2010) A multiple scale model for tumor growth. Multiscale Model Sim 3: 440-475.
30. Deisboeck T, Stamatakos G, (2010) Multiscale Cancer Modeling. Chapman & Hall/CRC mathe- matical and computational biology series. Taylor and Francis.
31. Rejniak K, Anderson A, (2011) Hybrid models of tumor growth. Wiley Interdisciplinary Rev Syst Biol Med 3: 115-125.
32. Fan L, Pepicelli C, Dibble C, Catbagan W, Zarycki J, et al. (2004) Hedgehog signaling promotes prostate xenograft tumor growth. Endocrinology 145: 3961.
33. Komarova S, Smith R, Dixon S, Sims S, Wahl L, (2003) Mathematical model predicts a critical role for osteoclast autocrine regulation in the control of bone remodeling. Bone 33: 206-215.
34. Komarova S, (2005) Mathematical model of paracrine interactions between osteoclasts and os-teoblasts predicts anabolic action of parathyroid hormone on bone. Endocrinology 146: 3589-3595.
35. Lam J, Takeshita S, Barker J, Kanagawa O, Ross F, et al. (2000) TNF-alpha induces osteoclasto-genesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 106: 1481-1499.
36. Guise T, Yin J, Taylor S, Kumagai Y, Dallas M, et al. (1996) Evidence for a causal role of parathy-roid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 98: 1544-1549.
37. Siclari V, Guise T, Chirgwin J, (2006) Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metast Rev 25: 621-633.
38. Tyson R, Stern L, LeVeque R, (2000) Fractional step methods applied to a chemotaxis model. J Math Biol 41: 455-475.
39. Kitazawa S, Kitazawa R, (2002) RANK ligand is a prerequisite for cancer-associated osteolytic lesions. J Pathol 198: 228-236.
40. Kalikin L, Schneider A, Thakur M, Fridman Y, Griffin L, et al. (2003) In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biol Ther 2: 656-660.
41. Schneider A, Kalikin L, Mattos A, Keller E, Allen M, et al. (2005) Bone turnover mediates pref-erential localization of prostate cancer in the skeleton. Endocrinology 146: 1727-1736.
42. Nagai M, Kyakumoto S, Sato N, (2000) Cancer Cells Responsible for Humoral Hypercalcemia Express mRNA Encoding a Secreted Form of ODF/TRANCE That Induces Osteoclast Formation* 1. Biochem Biophys Res Commun 269: 532-536.
43. Zhang J, Dai J, Qi Y, Lin D, Smith P, et al. (2001) Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107: 1235-1284.
44. Chikatsu N, Takeuchi Y, Tamura Y, Fukumoto S, Yano K, et al. (2000) Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro* 1. Biochem Biophys Res Commun 267: 632-637.
45. Thomas R, Guise T, Yin J, Elliott J, Horwood N, et al. (1999) Breast cancer cells interact with osteoblasts to support osteoclast formation. Endocrinology 140: 4451-4458.
46. Bhatia P, Sanders M, Hansen M, (2005) Expression of receptor activator of nuclear factor-κB ligand is inversely correlated with metastatic phenotype in breast carcinoma. Clin Cancer Res 11: 162-165.
47. Lapointe J, Li C, Higgins J, Van De Rijn M, Bair E, et al. (2004) Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci U S A 101: 811-816.
48. LaTulippe E, Satagopan J, Smith A, Scher H, Scardino P, et al. (2002) Comprehensive gene expres-sion analysis of prostate cancer reveals distinct transcriptional programs associated with metastatic disease. Cancer Res 62: 4499-4506.
49. Magee J, Araki T, Patil S, Ehrig T, True L, et al. (2001) Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 61: 5692-5696.
50. Ramaswamy S, Ross K, Lander E, Golub T, (2002) A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49-54.
51. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang C, et al. (2001) Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 98: 15149-15154.
52. Tomlins S, Mehra R, Rhodes D, Cao X, Wang L, et al. (2006) Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39: 41-51.
53. Vanaja D, Cheville J, Iturria S, Young C, (2003) Transcriptional silencing of zinc finger protein 185 identified by expression profiling is associated with prostate cancer progression. Cancer Res 63: 3877-3882.
54. Varambally S, Yu J, Laxman B, Rhodes D, Mehra R, et al. (2005) Integrative genomic and pro-teomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer cell 8: 393-406.
55. Yu Y, Landsittel D, Jing L, Nelson J, Ren B, et al. (2004) Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22: 2790-2799.
56. Boyce B, Xing L, (2008) Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473: 139-146.
57. Comerford I, Litchfield W, Harata-Lee Y, Nibbs R, McColl S, (2007) Regulation of chemotactic networks by 'atypical' receptors. Bioessays 29: 237-247.
58. Konopka T, Barker J, Bamford T, Guida E, Anderson R, et al. (2001) Nitric oxide synthase II gene disruption. Cancer Res 61: 3182-3187.